scholarly journals Circulating Levels of Bone Markers after Short-Term Intense Training with Increased Dairy Consumption in Adolescent Female Athletes

Children ◽  
2021 ◽  
Vol 8 (11) ◽  
pp. 961
Author(s):  
Panagiota Klentrou ◽  
Katherine McKee ◽  
Brandon J. McKinlay ◽  
Nigel Kurgan ◽  
Brian D. Roy ◽  
...  
Keyword(s):  
Female Athletes ◽  
Random Order ◽  
Female Adolescent ◽  
Placebo Control ◽  
Undercarboxylated Osteocalcin ◽  
Short Term ◽  
Double Blind ◽  
Training Assessment ◽  
Dairy Consumption ◽  
Intense Training

Thirteen female adolescent soccer players (14.3 ± 1.3 years) participated in a cross-over, double-blind trial examining the effects of Greek yogurt (GY) consumption on bone biomarkers during 5 days of intense soccer training. The study took place over two intervention weeks, which consisted of a pre-training assessment day, 5 training days, and a post-training assessment day. Participants completed the GY condition and a carbohydrate isocaloric placebo control pudding condition (CHO) in random order, 4 weeks apart. Morning, fasted, resting blood samples were collected pre- and post-training in each condition. Total osteocalcin (tOC), undercarboxylated osteocalcin (unOC), C-terminal telopeptide of type 1 collagen (CTX), osteoprotegerin (OPG), and receptor activator nuclear factor kappa-β ligand (RANKL) were measured in serum. The results showed no effects for time (pre- to post-training) or condition, and no interaction for tOC, CTX, OPG, RANKL, and the OPG/RANKL ratio. A time-by-condition interaction (p = 0.011) was observed in unOC, reflecting a post-training decrease in the GY, but not the CHO condition (−26% vs. −3%, respectively). However, relative unOC (% of tOC) decreased post-training (−16%), with no differences between conditions. These findings suggest that short-term high-impact intense training had no direct catabolic impact on bone metabolism, with GY adding no benefit beyond that of the isocaloric CHO control pudding.

Analysis of acute naproxen administration on memory in young adults: A randomized, double-blind, placebo-controlled study

2017 ◽  
Vol 31 (10) ◽  
pp. 1374-1376
Author(s):  
Jack H Wilson ◽  
Amy H Criss ◽  
Sean A Spangler ◽  
Katherine Walukevich ◽  
Sandra Hewett
Keyword(s):  
Young Adults ◽  
Healthy Adult ◽  
Adult Population ◽  
Critical Role ◽  
Random Order ◽  
Controlled Study ◽  
High Dose ◽  
Short Term ◽  
Double Blind ◽  
Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs work by non-selectively inhibiting cyclooxygenase enzymes. Evidence indicates that metabolites of the cyclooxygenase pathway play a critical role in the process of learning and memory. We evaluated whether acute naproxen treatment impairs short-term working memory, episodic memory, or semantic memory in a young, healthy adult population. Participants received a single dose of placebo or naproxen (750 mg) in random order separated by 7–10 days. Two hours following administration, participants completed five memory tasks. The administration of acute high-dose naproxen had no effect on memory in healthy young adults.

Short-term Dehydroepiandrosterone Intake and Supramaximal Exercise in Young Recreationally-trained Women

2018 ◽  
Vol 39 (09) ◽  
pp. 712-719 ◽  
Author(s):  
Nicolas Gravisse ◽  
Nancy Vibarel-Rebot ◽  
Zakaria Labsy ◽  
Manh-Cuong Do ◽  
Olivier Gagey ◽  
...  
Keyword(s):  
Body Composition ◽  
Female Athletes ◽  
Bioelectrical Impedance ◽  
Young Female ◽  
Anaerobic Exercise ◽  
Ergogenic Effect ◽  
Improve Performance ◽  
Short Term ◽  
Double Blind ◽  
Significant Difference

AbstractWADA has banned dehydroepiandrosterone (DHEA) but its ergogenic effect in female athletes has never been investigated. The aim of this study was to determine whether short-term DHEA intake would improve performance during a supramaximal field exercise in healthy young recreationally trained women. Its impact on body composition, metabolic responses was also measured. Eleven young female volunteers completed four running-based anaerobic sprint tests: just before and after treatment with either oral placebo or DHEA (100 mg/day/28days), following a double-blind and randomized protocol. Bioelectrical impedance assessed body composition. At rest and after passive recovery, blood samples were collected for lactate measurement and saliva samples for DHEA, testosterone and cortisol analysis. There was no significant difference in body composition or performance parameters after DHEA administration, despite a tendency toward increased peak power and decreased fat mass. However, DHEA treatment induced a very marked increase in saliva DHEA and testosterone concentrations (p<0.001), with no change in cortisol or lactate levels. In conclusion, short-term DHEA administration did not improve performance or have an anabolic effect in young female recreationally trained athletes, despite the increase in androgenic hormones. Further studies are needed to determine whether a higher daily dose would generate an ergogenic effect during anaerobic exercise.

scholarly journals Effect of Pea Hull Fiber on Uremic Metabolites and Gut Microbiota Composition in Individuals Undergoing Hemodialysis

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 1155-1155
Author(s):  
Asmaa Fatani ◽  
JoonHyuk Suh ◽  
Jeremie Auger ◽  
Yu Wang ◽  
Wendy Dahl
Keyword(s):  
Random Order ◽  
Serum Levels ◽  
Amplicon Sequencing ◽  
Future Research ◽  
Placebo Control ◽  
Rrna Gene ◽  
Microbiota Composition ◽  
Double Blind ◽  
Fecal Microbiome ◽  
Hull Fiber

Abstract Objectives The objective was to determine the effects of pea hull fiber intake on serum uremic molecules and microbiota composition of individuals undergoing hemodialysis. Methods A randomized, double-blind, placebo-control, crossover study was conducted with individuals undergoing hemodialysis. Following a 1-week baseline, participants consumed muffins with added pea hull fiber (15 g/d) and control muffins daily for 4 weeks in random order, separated by a 4-week washout. Blood and stool samples were collected during each period. Serum p-cresol sulfate (PCS), indoxyl sulfate (IS) and trimethylamine N-oxide (TMAO) were analyzed by LC–MS/MS and fecal microbiome profile by 16S rRNA gene amplicon sequencing. qPCR for taxa of interest (Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium, and Roseburia) was performed. QIIME 2 sample-classifier was used to discover a unique microbiota profile due to the consumption of pea hull fiber. Results Of the 18 participants randomized (50 ± 4 y; eGFR 6.6 ± 0.7 ml/min/1.73m2), 13 completed the study. No significant changes from baseline were observed in serum PCS (3256 ± 505 μmol/L), IS (166 ± 23 μmol/L) or TMAO (96 ± 12 μmol/L), or for the relative quantification of A. muciniphila, F. prausnitzii, Bifidobacterium, and Roseburia, taxa thought to be health enhancing. Taxa that most distinguished the microbiota composition during the pea hull fiber intervention from usual diet periods were enriched Gemmiger, Collinsella and depleted Lactobacillus, Ruminococcus, Coprococcus and Mogibacteriaceae. Given that abundance of Collinsella has been inversely associated with dietary fiber, this finding was unexpected. Conclusions In dialysis patients, added pea hull fiber did not reduce the serum levels of targeted uremic molecules but did alter fecal microbiota composition. Future research in this patient population should explore the efficacy of alternate fiber sources or plant-based dietary patterns for reducing serum levels of uremic toxins. Funding Sources Saskatchewan Pulse Growers.

Evaluation of the Efficacy of ST2 and NT-proBNP in the Diagnosis and Prediction of Short- Term Prognosis in Heart Failure with Reduced Ejection Fraction

2017 ◽  
Vol 9 (04) ◽  
Author(s):  
Shivananda B Nayak ◽  
Dharindra Sawh ◽  
Brandon Scott ◽  
Vestra Sears ◽  
Kareshma Seebalack ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Cardiac Biomarkers ◽  
Double Blind Study ◽  
Short Term ◽  
Double Blind ◽  
Reduced Ejection Fraction ◽  
The Mean ◽  
Design And Methods ◽  
The Relationship

Purpose: i) To determine the relationship between the cardiac biomarkers ST2 and NT-proBNP with ejection fraction (EF) in heart failure (HF) patients. ii) Assess whether a superiority existed between the aforementioned cardiac markers in diagnosing the HF with reduced EF. iii) Determine the efficacy of both biomarkers in predicting a 30-day cardiovascular event and rehospitalization in patients with HF with reduced EF iv) To assess the influence of age, gender, BMI, anaemia and renal failure on the ST2 and NT-proBNP levels. Design and Methods: A prospective double-blind study was conducted to obtain data from a sample of 64 cardiology patients. A blood sample was collected to test for ST2 and NT-proBNP. An echocardiogram (to obtain EF value), electrocardiogram and questionnaire were also obtained. Results: Of the 64 patients enrolled, 59.4% of the population had an EF less than 40%. At the end of the 30- day period, 7 patients were warded, 37 were not warded, one died and 17 were non respondent. Both biomarkers were efficacious at diagnosing HF with a reduced EF. However, neither of them were efficacious in predicting 30-day rehospitalization. The mean NT-proBNP values being: not rehospitalized (2114.7486) and 30 day rehospitalization (1008.42860) and the mean ST2 values being: not rehospitalized (336.1975), and 30-day rehospitalization. (281.9657). Conclusion: Neither ST2 or NT-proBNP was efficacious in predicting the short- term prognosis in HF with reduced EF. Both however were successful at confirming the diagnosis of HF in HF patients with reduced EF.

Evaluating Thrombin Inhibition in Alzheimer’s Disease (The BEACON Trial): Protocol for a Pilot Study (Preprint)

2019 ◽  
Author(s):  
Cláudia Yang Santos ◽  
Christine Getter ◽  
John Stoukides ◽  
Brian Ott ◽  
Stephen Salloway ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pilot Study ◽  
Cognitive Performance ◽  
Thrombin Inhibitor ◽  
Placebo Control ◽  
Open Label ◽  
Double Blind ◽  
Thrombin Inhibition ◽  
Approved Drugs

BACKGROUND The precise mechanisms whereby cardiovascular risk factors increase the risk of Alzheimer’s disease (AD) have not been delineated. We reported that microvessels isolated from AD brains overexpress a diverse array of neurotoxic and inflammatory proteins, which is consistent with the process of vascular activation. In pre-clinical studies using AD animal models we showed that a vascular activation inhibitor reduced vascular-derived neuroinflammation and improved cognitive performance. Thrombin is a key mediator of cerebrovascular activation in AD. OBJECTIVE This study aims to investigate the safety and potential efficacy of the direct thrombin inhibitor dabigatran, in patients with mild cognitive impairment (MCI) or mild AD to decrease vascular-derived neuroinflammation and improve cognitive performance. METHODS Participants will be enrolled then evaluated quarterly throughout the 24-month study. This is a 24-month randomized-control, double-blind, placebo-controlled, multicenter, delayed-start, pilot study evaluating thrombin inhibition in people with biomarker-confirmed MCI probably due to AD or mild AD. 40 - 60 participants will be recruited between 50 - 85 years old. In the initial 9-months of study, either dabigatran or placebo will be orally administered to patients at a dose of 150 mg per day. After 9 months of the placebo-control (Phase I), the placebo arm will cross-over to an active, open-label (Phase II) where all patients will be treated with a 150 mg daily dose of dabigatran orally for an additional 12 months. A 3-month non-treatment follow-up period will assess duration of effects. RESULTS Beginning in July 2019, and concluding in August 2022, this study is expected to publish final results in January 2023. CONCLUSIONS BEACON is a first-in-kind randomized clinical trial targeting thrombin activation in AD therapeutics. This trial will stimulate translational investigations of an FDA-approved drugs in a newly defined therapeutic areas. CLINICALTRIAL Clinicaltrials.gov NCT03752294

Sign in / Sign up

Export Citation Format

Share Document